• All Share : 48362.22
    UNCHANGED0.00%
    Top 40 : 4183.85
    UNCHANGED0.00%
    Financial 15 : 13650.32
    UNCHANGED0.00%
    Industrial 25 : 54866.52
    UNCHANGED0.00%

  • ZAR/USD : 10.4895
    UNCHANGED0.00%
    ZAR/GBP : 17.5997
    UNCHANGED0.00%
    ZAR/EUR : 14.4818
    UNCHANGED0.00%
    ZAR/JPY : 0.1024
    UNCHANGED0.00%
    ZAR/AUD : 9.7819
    UNCHANGED0.00%

  • Gold : 1294.9000
    UNCHANGED0.00%
    Platinum : 1407.5000
    UNCHANGED0.00%
    Silver : 19.5700
    UNCHANGED0.00%
    Palladium : 794.0000
    UNCHANGED0.00%
    Brent Crude Oil : 109.530
    UNCHANGED0.00%

  • All data is delayed by 15 min. Data supplied by I-Net Bridge
    Hover cursor over this ticker to pause.

Sun Apr 20 18:49:22 SAST 2014

Australian research provides final clue for anti-malaria drug

Reuters | 19 February, 2013 12:07
Mosquito-borne diseases. Species of the blood-sucking insects that can carry exotic-sounding tropical infections like malaria
A mosquito on a human finger. File photo.
Image by: HANDOUT / REUTERS

Researchers in Australia have provided the final piece of a puzzle to develop a new anti-malarial drug, which targets the parasite that causes the disease and kills it with a salt overdose.

The drug, the first discovery in the fight against malaria in two decades, holds out fresh hope for conquering the disease, which claims hundreds of thousands of lives a year and is known for its evolving drug resistance.

The malaria parasite, carried to humans by mosquitoes, lives in red blood cells, which are full of salt. To survive, researchers knew it had to have a way of filtering salt out of its body.

“The parasite is quite leaky, it’s letting salt in all the time. But that doesn’t matter because it’s got a very effective molecular salt pump that keeps pushing the salt out again,” said Professor Kiaran Kirk, director at the Research School of Biology at Australia National University (ANU).

Research teams in the United States and Singapore had developed a drug that attacked the protein that makes up the salt pump, but it wasn’t until the ANU researchers tested it that they confirmed it worked effectively.

“On the one hand, they had a brand new drug, they didn’t know how it worked,” Kirk said.

“We knew a lot about salt and salt pumps, and it was clear their drug was knocking out our salt pump. That led us to work together.”

The drug attacks the salt pump and disables it, causing the parasite to fill up with salt and die. Targeting such a basic function is crucial because malaria tends to evolve quickly, rendering other drugs ineffective.

Other drugs that combat malaria combine or package older drugs together or are altered chemically.

“This is actually the first drug for 20 years to be genuinely new,” Kirk said. “Targeting the pump protein is a structure that has never been used before to treat malaria.”

The drug is undergoing clinical trials and it will be several years at least before it hits the market. The other two groups involved are the Novartis Institutes for Tropical Disease in Singapore and the Genomics Institute of the Novartis research Foundation.

Malaria infects more than 200 million people worldwide every year and kills around 600 000 of them — primarily children under the age of five in sub-Saharan Africa.

Experts say one of the most challenging features of this parasite is its ability to evolve and overcome anti-malarial drugs — a factor that is undermining global work towards eradicating the killer disease.

SHARE YOUR OPINION

If you have an opinion you would like to share on this article, please send us an e-mail to the Times LIVE iLIVE team. In the mean time, click here to view the Times LIVE iLIVE section.
Sun Apr 20 18:49:22 SAST 2014 ::